OBJECTIVE: Multiple biomarkers are used to assess sepsis severity and prognosis. Increased levels of the soluble receptor for advanced glycation end products (sRAGE) were previously observed in sepsis but also in end-organ injury without sepsis. We evaluated associations between sRAGE and (i) 28-day mortality, (ii) sepsis severity, and (iii) individual organ failure. Traditional biomarkers procalcitonin (PCT), C-reactive protein (CRP) and lactate served as controls. METHODS: sRAGE, PCT, CRP, and lactate levels were observed on days 1 (D1) and 3 (D3) in 54 septic patients. We also assessed the correlation between the biomarkers and acute respiratory distress syndrome (ARDS), acute kidney injury (AKI) and acute heart failure. RESULTS: There were 38 survivors and 16 non-survivors. On D1, non-survivors had higher sRAGE levels than survivors (p = 0.027). On D3, sRAGE further increased only in non-survivors (p < 0.0001) but remained unchanged in survivors. Unadjusted odds ratio (OR) for 28-day mortality was 8.2 (95% CI: 1.02-60.64) for sRAGE, p = 0.048. Receiver operating characteristic analysis determined strong correlation with outcome on D3 (AUC = 0.906, p < 0.001), superior to other studied biomarkers. sRAGE correlated with sepsis severity (p < 0.00001). sRAGE showed a significant positive correlation with PCT and CRP on D3. In patients without ARDS, sRAGE was significantly higher in non-survivors (p < 0.0001) on D3. CONCLUSION: Increased sRAGE was associated with 28-day mortality in patients with sepsis, and was superior compared to PCT, CRP and lactate. sRAGE correlated with sepsis severity. sRAGE was increased in patients with individual organ failure. sRAGE could be used as an early biomarker in prognostication of outcome in septic patients.
OBJECTIVE: Multiple biomarkers are used to assess sepsis severity and prognosis. Increased levels of the soluble receptor for advanced glycation end products (sRAGE) were previously observed in sepsis but also in end-organ injury without sepsis. We evaluated associations between sRAGE and (i) 28-day mortality, (ii) sepsis severity, and (iii) individual organ failure. Traditional biomarkers procalcitonin (PCT), C-reactive protein (CRP) and lactate served as controls. METHODS: sRAGE, PCT, CRP, and lactate levels were observed on days 1 (D1) and 3 (D3) in 54 septicpatients. We also assessed the correlation between the biomarkers and acute respiratory distress syndrome (ARDS), acute kidney injury (AKI) and acute heart failure. RESULTS: There were 38 survivors and 16 non-survivors. On D1, non-survivors had higher sRAGE levels than survivors (p = 0.027). On D3, sRAGE further increased only in non-survivors (p < 0.0001) but remained unchanged in survivors. Unadjusted odds ratio (OR) for 28-day mortality was 8.2 (95% CI: 1.02-60.64) for sRAGE, p = 0.048. Receiver operating characteristic analysis determined strong correlation with outcome on D3 (AUC = 0.906, p < 0.001), superior to other studied biomarkers. sRAGE correlated with sepsis severity (p < 0.00001). sRAGE showed a significant positive correlation with PCT and CRP on D3. In patients without ARDS, sRAGE was significantly higher in non-survivors (p < 0.0001) on D3. CONCLUSION: Increased sRAGE was associated with 28-day mortality in patients with sepsis, and was superior compared to PCT, CRP and lactate. sRAGE correlated with sepsis severity. sRAGE was increased in patients with individual organ failure. sRAGE could be used as an early biomarker in prognostication of outcome in septicpatients.
Authors: Sergio Raposeiras-Roubín; Bruno K Rodiño-Janeiro; Lilian Grigorian-Shamagian; María Moure-González; Ana Seoane-Blanco; Alfonso Varela-Román; Ezequiel Alvarez; José R González-Juanatey Journal: Eur J Heart Fail Date: 2010-08-03 Impact factor: 15.534
Authors: G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R LeGall; A Morris; R Spragg Journal: Intensive Care Med Date: 1994 Impact factor: 17.440
Authors: Sari Karlsson; Milja Heikkinen; Ville Pettilä; Seija Alila; Sari Väisänen; Kari Pulkki; Elina Kolho; Esko Ruokonen Journal: Crit Care Date: 2010-11-15 Impact factor: 9.097
Authors: Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: Christian Bopp; Angelika Bierhaus; Stefan Hofer; Axel Bouchon; Peter P Nawroth; Eike Martin; Markus A Weigand Journal: Crit Care Date: 2008-01-09 Impact factor: 9.097
Authors: Michelle J Lim; Matt S Zinter; Lucia Chen; Kayley Man Yee Wong; Anoopindar Bhalla; Kinisha Gala; Mona Guglielmo; Mustafa Alkhouli; Leanna L Huard; Mark R Hanudel; Sitaram Vangala; Andreas Schwingshackl; Michael Matthay; Anil Sapru Journal: Crit Care Med Date: 2021-10-25 Impact factor: 9.296
Authors: John H Meertens; Hans L Nienhuis; Joop D Lefrandt; Casper G Schalkwijk; Kristiina Nyyssönen; Jack J M Ligtenberg; Andries J Smit; Jan G Zijlstra; D J Mulder Journal: PLoS One Date: 2016-08-16 Impact factor: 3.240
Authors: Matthieu Jabaudon; Raiko Blondonnet; Bruno Pereira; Rodrigo Cartin-Ceba; Christoph Lichtenstern; Tommaso Mauri; Rogier M Determann; Tomas Drabek; Rolf D Hubmayr; Ognjen Gajic; Florian Uhle; Andrea Coppadoro; Antonio Pesenti; Marcus J Schultz; Marco V Ranieri; Helena Brodska; Ségolène Mrozek; Vincent Sapin; Michael A Matthay; Jean-Michel Constantin; Carolyn S Calfee Journal: Intensive Care Med Date: 2018-07-26 Impact factor: 17.440